---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-054630"
form_type: "8-K"
ticker: "ROIV"
cik: "0001635088"
company_name: "Roivant Sciences Ltd."
filed_at: "2023-11-27T23:59:59+00:00"
generated_at: "2026-06-07T21:29:38.869395+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Roivant subsidiary Priovant's Phase 2 lupus study of oral brepocitinib fails primary endpoint

## Summary
- Oral brepocitinib did not meet primary endpoint of SRI-4 at Week 52 in moderate-to-severe active lupus.
- Highest placebo response rate observed in any significant SLE study prevented differentiation; active arm showed high SRI-4 rates.
- Priovant will not progress brepocitinib in SLE but continues in non-infectious uveitis and dermatomyositis.
- Topline results for NIU Phase 2 expected Q1 2024; dermatomyositis Phase 3 topline in 2025.

## SEC filing metadata
- accession: 0001140361-23-054630
- form_type: 8-K
- ticker: ROIV
- cik: 0001635088
- company_name: Roivant Sciences Ltd.
- filed_at: 2023-11-27T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1635088/000114036123054630/0001140361-23-054630-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1635088/000114036123054630/ef20015420_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-054630
- JSON: https://secwatch.observer/filing/0001140361-23-054630.json
- Plain text: https://secwatch.observer/filing/0001140361-23-054630.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.